These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26518895)

  • 21. Pancreatic cancer stem cells: their role in pancreatic cancer patient outcomes and what is future?
    Habib M; Saif MW
    JOP; 2013 Jul; 14(4):401-4. PubMed ID: 23846937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niche Mimicking for Selection and Enrichment of Liver Cancer Stem Cells by Hyaluronic Acid-Based Multilayer Films.
    Lee IC; Chuang CC; Wu YC
    ACS Appl Mater Interfaces; 2015 Oct; 7(40):22188-95. PubMed ID: 26379083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of CD133 in synovial sarcoma.
    Terry J; Nielsen T
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXM1-Induced PRX3 Regulates Stemness and Survival of Colon Cancer Cells via Maintenance of Mitochondrial Function.
    Song IS; Jeong YJ; Jeong SH; Heo HJ; Kim HK; Bae KB; Park YH; Kim SU; Kim JM; Kim N; Ko KS; Rhee BD; Han J
    Gastroenterology; 2015 Oct; 149(4):1006-16.e9. PubMed ID: 26091938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [An update: stem cell and cancer stem cells].
    Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2009 Aug; 38(8):511-2. PubMed ID: 20021959
    [No Abstract]   [Full Text] [Related]  

  • 26. Biology and clinical implications of CD133(+) liver cancer stem cells.
    Ma S
    Exp Cell Res; 2013 Jan; 319(2):126-32. PubMed ID: 22999864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
    Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
    Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice.
    Dou J; He XF; Cao WH; Zhao FS; Wang XY; Liu YR; Wang J
    Cell Mol Biol (Noisy-le-grand); 2013 Oct; Suppl 59():OL1861-8. PubMed ID: 24120113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer stem cell biomarkers for head and neck squamous cell carcinoma: A bioinformatic analysis.
    Xiao M; Liu L; Zhang S; Yang X; Wang Y
    Oncol Rep; 2018 Dec; 40(6):3843-3851. PubMed ID: 30542719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges.
    Grosse-Gehling P; Fargeas CA; Dittfeld C; Garbe Y; Alison MR; Corbeil D; Kunz-Schughart LA
    J Pathol; 2013 Feb; 229(3):355-78. PubMed ID: 22899341
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting CD133 antigen in cancer.
    Ferrandina G; Petrillo M; Bonanno G; Scambia G
    Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The utility of CD44, CD117 and CD133 in identification of cancer stem cells (CSC) in oral squamous cell carcinomas (OSCC).
    Mărgăritescu C; Pirici D; Simionescu C; Stepan A
    Rom J Morphol Embryol; 2011; 52(3 Suppl):985-93. PubMed ID: 22119814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Crosstalk-eliminated quantitative determination of aflatoxin B1-induced hepatocellular cancer stem cells based on concurrent monitoring of CD133, CD44, and aldehyde dehydrogenase1.
    Ju H; Shim Y; Arumugam P; Song JM
    Toxicol Lett; 2016 Jan; 243():31-9. PubMed ID: 26739636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of cancer stem cell markers CD133 and CD44 in locoregional recurrence of rectal cancer.
    Nagata T; Sakakura C; Komiyama S; Miyashita A; Nishio M; Murayama Y; Komatsu S; Shiozaki A; Kuriu Y; Ikoma H; Nakanishi M; Ichikawa D; Fujiwara H; Okamoto K; Ochiai T; Kokuba Y; Sonoyama T; Otsuji E
    Anticancer Res; 2011 Feb; 31(2):495-500. PubMed ID: 21378329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour-initiating cells vs. cancer 'stem' cells and CD133: what's in the name?
    Neuzil J; Stantic M; Zobalova R; Chladova J; Wang X; Prochazka L; Dong L; Andera L; Ralph SJ
    Biochem Biophys Res Commun; 2007 Apr; 355(4):855-9. PubMed ID: 17307142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer stem cells in head and neck squamous cell carcinoma: a review of current knowledge and future applications.
    Bhaijee F; Pepper DJ; Pitman KT; Bell D
    Head Neck; 2012 Jun; 34(6):894-9. PubMed ID: 21850700
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
    Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
    Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Progress of research on breast cancer stem cell markers].
    Liu X; Li W; Fu L
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):282-4. PubMed ID: 24915825
    [No Abstract]   [Full Text] [Related]  

  • 39. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
    Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
    Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
    Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
    Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.